Completed NA INTERVENTIONAL 2-arm NCT02896413

The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

Sponsor: Yonsei University

Interventions Control group Dexmedetomidine group

Updated 9 times since 2017 Last updated: May 3, 2021 Started: Jun 2, 2016 Primary completion: Oct 24, 2018 Completion: Oct 24, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Uterine Cancer and is currently completed. Yonsei University leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2021 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Feb 2021 — Jun 2021 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status

▶ Show 4 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting NA
Feb 2019 — Jan 2021 [monthly]

Recruiting NA

Status: Unknown Status → Recruiting
Oct 2018 — Feb 2019 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2017 — Oct 2018 [monthly]

Recruiting NA

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yonsei University

Data source: Yonsei University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea